Norepinephrine-dopamine reuptake inhibitor

From Wikipedia, the free encyclopedia
Jump to: navigation, search

A norepinephrine-dopamine reuptake inhibitor (NDRI) is a drug that acts as a reuptake inhibitor for the neurotransmitters norepinephrine and dopamine by blocking the action of the norepinephrine transporter (NET) and the dopamine transporter (DAT), respectively.[1] This in turn leads to increased extracellular concentrations of both norepinephrine and dopamine and, therefore, an increase in adrenergic and dopaminergic neurotransmission.[1]


Norepinephrine-dopamine reuptake inhibitors are used for Clinical depression, ADD, ADHD, Narcolepsy, and as antiparkinson agents.

List of NDRIs[edit]

Many NDRIs exist, including the following:

Amphetamine and nearly all of it's derivatives, the substituted amphetamines are also competitive inhibitors of the Norepinephrine and Dopamine transporter proteins. Amphetamine, itself also has very minor affinity for the Serotonin Transporter. But this action is rather insignificant, which is why amphetamine is usually classified as a NDRI. However, the substituted amphetamines have a very diverse effects profile, and many of them do, infact, have significant inhibiting effects on the SERT.

In addition to blocking the reuptake of Norepinephrine and Dopamine, Amphetamine, and many of the other substituted amphetamines are potent agonists of the Trace-amine Associated Receptor (abbreviated as TAAR). Agonization of this receptor induces the phosphorylation of the respective transporter proteins, and actually causes them to reverse their action; remove trace amines from the inside of the cell and put them back into the post-synaptic cleft.

This action as well as Amphetamine effects on the inhibition of VMAT2 greatly contribute to it's effects. This makes it's effects profile much different than classical NDRI's.

Note: Only NDRIs selective for the NET and DAT over the serotonin transporter (SERT) are listed here. For a list of NDRIs that also act at the SERT, see the SNDRI page.

Research Compounds[edit]

CA 2711977.svg
CA 2711977 
Compound 5-HT-uptake IC50(μM) DA-uptake IC50(μM) NA-uptake IC50(μM)
Piperidine-4-carboxylic (3,4-dichloro-phenyl)-ethyl-amide 0.37 0.021 0.0097
Piperidine-4-carboxylic (3-bromo-4-chloro-phenyl)-ethyl-amide 0.14 0.0078 0.005
Piperidine-4-carboxylic (3-4-dibromo-phenyl)-ethyl-amide 0.12 0.0040 0.0031
US 2011263651 
Compound 5-HT-uptake IC50(μM) DA-uptake IC50(μM) NA-uptake IC50(μM)
N-(3,4-Dichloro-phenyl)-N-ethyl-4-piperidin-4-yl-butyramide 0.57 0.012 0.030
N-(3,4-Dichloro-phenyl)-N-ethyl-4-(1-methyl-piperidin-4-yl)-butyramide 0.80 0.0069 0.012

See also[edit]


  1. ^ a b Stephen M. Stahl (2 March 2009). Antidepressants. Cambridge University Press. p. 73. ISBN 978-0-521-75852-9. Retrieved 10 May 2012.